Sanofi–Translate Bio COVID-19 vaccine
This is an old revision of this page, as edited by 2001:a61:2a42:f201:d17e:edb:23d:5449 (talk) at 21:55, 31 December 2021. The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.
Vaccine description | |
---|---|
Target | SARS-CoV-2 |
Vaccine type | mRNA |
Clinical data | |
Other names | MRT5500, VAW00001 |
Routes of administration | Intramuscular |
Legal status | |
Legal status |
|
Part of a series on the |
COVID-19 pandemic |
---|
![]() |
|
Medical response |
|
![]() |
The Sanofi–Translate Bio COVID-19 vaccine, also known as MRT5500 or VAW00001, was a COVID-19 vaccine candidate developed by Sanofi Pasteur and Translate Bio.[2][3] The development was stopped in September 2021.[4]
History
In June 2020, Sanofi, after lagging behind its competitors, "accelerated" the development of the vaccine via the smaller biotech firm Translate Bio, with a US$425 million partnership.[5]
Development of the vaccine halted in September 2021, with Sanofi citing the difficulty of running placebo-controlled studies with other mRNA vaccines (such as Pfizer's and Moderna's) already on the market. Despite this, the company reported "promising results" in its initial trials.[4]
Sanofi has continued testing its recombinant protein vaccine, developed collaboratively with GlaxoSmithKline, to serve as a booster dose for other COVID-19 vaccines.[4]
References
- ^ Abboud L (28 September 2021). "Sanofi stops development of Covid vaccine based on mRNA technology". Financial Times.
- ^ "Sanofi and Translate Bio initiate Phase 1/2 clinical trial of mRNA COVID-19 vaccine candidate". Sanofi. 12 March 2021. Archived from the original on 9 October 2021. Retrieved 20 March 2021.
- ^ "Study of mRNA Vaccine Formulation Against COVID-19 in Healthy Adults 18 Years of Age and Older (VAW00001)". United States National Library of Medicine. Retrieved 20 March 2021.
{{cite web}}
: CS1 maint: url-status (link) - ^ a b c "Sanofi drops plans for messenger RNA vaccine against virus". Associated Press. 28 September 2021. Archived from the original on 13 October 2021. Retrieved 7 October 2021.
{{cite news}}
:|archive-date=
/|archive-url=
timestamp mismatch; 14 October 2021 suggested (help) - ^ Branswell H, Feuerstein A (23 June 2020). "Sanofi, a straggler in the Covid-19 vaccine race, accelerates its plans". STAT. Archived from the original on 19 October 2021. Retrieved 7 August 2020.
{{cite news}}
:|archive-date=
/|archive-url=
timestamp mismatch; 20 October 2021 suggested (help)
External links
![](http://upload.wikimedia.org/wikipedia/commons/thumb/3/32/Scholia_logo.svg/40px-Scholia_logo.svg.png)
Development | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Classes | |||||||||||
Administration | |||||||||||
Vaccines |
| ||||||||||
Inventors/ researchers | |||||||||||
Controversy | |||||||||||
Related | |||||||||||
|
![]() | This article about COVID-19 vaccines is a stub. You can help Wikipedia by expanding it. |
![]() | This article about vaccines or vaccination is a stub. You can help Wikipedia by expanding it. |
- CS1 maint: url-status
- CS1 errors: archive-url
- Articles with short description
- Short description matches Wikidata
- Use dmy dates from April 2021
- Drugs with non-standard legal status
- Chemical articles without CAS registry number
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs missing an ATC code
- Articles containing unverified chemical infoboxes
- Drugs that are a vaccine
- All stub articles